Fosun Pharma’s Revenue And Profit Will Double In 2025, With Innovative Drugs Becoming Growth Engine
Recently, Fosun Pharma announced that it will achieve operating income of RMB 41.662 billion in 2025, a year-on-year increase of 1.45%, and net profit attributable to parent companies of RMB 3.371 billion, a year-on-year increase of 21.69%. Among which, revenue from innovative drugs was 9.893 billion yuan




















